News

BlogsPosts
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the
BlogsPosts
As Seen In
Is the Age-Old Quest for a Baldness Cure Reaching Its End?
Click here to read the full article and interview as it appears
BlogsPosts
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon
BlogsPosts
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal
BlogsPosts
As Seen In
Analyst Says Cell Therapy Company’s Move Decreases Risk
Click here to read the full article as
BlogsPosts
As Seen In
Skin in the Game
To read the full article as it appears on DDN News (08/08/17), click here.
BlogsPosts
As Seen In
Hair-Raising R&D: RepliCel Developing Autologous Cell Therapy for Baldness
To read the full article as it appears on BioPharma-reporter.com, click here. (7/12/17)
BlogsPosts
As Seen In
Poised for Success with Positive Clinical Results
To read the full interview as it appears on Costmeticosbr.com.br, click here (7/6/17).
BlogsPosts
As Seen In
A New Approach to Treating Hair Loss
To read the full interview as it appears on Technologyworks.com, click here. (6/27/17)
BlogsPosts
As Seen In
The Latest in Biocellular Regeneration
To read the full article as it appears on TheAestheticChannel.com by Lisette Hilton, click here
BlogsPosts
Press Release
RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Data from this project expected to take RepliCel’s products to next level of potential commercial
BlogsPosts
As Seen In
Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler
To read the full article as it appears on SmarterAnalyst.com by Julie Lamb, click here.
BlogsPosts
Press Release
RepliCel CEO Provides Company Outlook
A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,
BlogsPosts
As Seen In
RepliCel Developing Autologous Cell Therapies For Skin, Hair and Tendon Regeneration
To read the full interview as it appears on MedicalResearch.com, click here. (4/22/17)
BlogsPosts
As Seen In
RepliCel – Stem Cell Therapies Using Your Own Cells
To listen to Podcast and View Transcript on Future Tech Podcast, click here
BlogsPosts
Press Release
RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy VANCOUVER,
BlogsPosts
As Seen In
RepliCel – Using Cells for Healing
View featured company Article on Advisor Access click here
BlogsPosts
As Seen In
RepliCel CEO Lee Buckler talks to Cantech Letter
View Article by Nick Waddell on Cantech Letter click here
BlogsPosts
Press Release
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)
BlogsPosts
Press Release
RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.